Lenalidomid Sandoz

Lenalidomide, the active ingredient in Lenalidomid Sandoz, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q) and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomid Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier, ensuring quality and regulatory compliance for hospitals, oncology centres, pharmacies and clinics worldwide. The company leverages a global distribution network to meet demand in both mature and emerging markets.

Lenalidomide is an immunomodulatory antineoplastic agent used in specific hematologic malignancies and related disorders.

- Multiple myeloma: improves progression‑free survival, overall response rates and depth of response when combined with dexamethasone or other standard regimens. - Myelodysplastic syndromes with del(5q): induces transfusion independence, reduces red‑cell transfusion requirements and can achieve cytogenetic remission in patients harboring the del(5q) abnormality. - Mantle cell lymphoma: provides disease control and prolongs remission duration in relapsed or refractory cases, often administered together with rituximab or other targeted therapies.